Antibodies, traditionally used as drugs due to scientists’ manipulation, have limitations in their therapeutic window. Archon Biosciences, a Seattle-based startup, has developed a technology that changes the size and shape of antibodies, creating “antibody cages” or AbCs. These AbCs offer tunability not found in natural antibodies, allowing for autonomous activation of pathways within cells. The technology, developed at the University of Washington, has received $20 million in funding and aims to target well-characterized but elusive therapeutic indications. Archon plans to use their funding to build a strong business case and eventually partner with larger pharmaceutical companies.
Source link
Protein-Design Startup Archon Adds $20M to Show How ‘Cages’ Can Change Antibody Drugs
